Loading
Latest filing published 19 Jun 2016 for Zenith Epigenetics Corp., €2,704.
No signal scores available.
This profile gathers the share dealings of Aaron Bradley Cann in Zenith Epigenetics Corp. Over a trading history stretching from 26 May 2016 to 14 June 2016, the count stands at 2 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 19 June 2016, reports an option exercise of €2,704 in Zenith Epigenetics Corp. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations